Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 22Genitourinary 12Tumor-Agnostic 9Gastrointestinal 8Thoracic 7Breast 5Sarcoma 4Lymphoid 3Gynecologic 3Other solid neoplasm 2Head & Neck 2CNS 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Mesothelioma 13Mesothelioma, Malignant 7Carcinoma, Non-Small-Cell Lung 5Solid Tumor 4Ovarian Neoplasms 3Melanoma 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor, Adult 2Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Lung Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Turcot syndrome 1Skin Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Microsatellite Unstable Colorectal Cancer 1Metastatic Solid Tumors 1Liver Neoplasms 1Kidney Neoplasms 1Esophageal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

pembrolizumab 7Nivolumab 2Ipilimumab 2Cyclophosphamide 2Cisplatin 2spartalizumab 1regorafenib 1rebastinib 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1aldesleukin 1abemaciclib 1Tomography, Optical Coherence 1Talc 1Tablets 1Sirolimus 1Radiofrequency Ablation 1Pemetrexed 1Paclitaxel 1Mitomycin 1Midazolam 1Levoleucovorin 1Leucovorin 1Letrozole 1LY3023414 1Interleukin-2 1Injections 1Immunologic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Ipilimumab × Other solid neoplasm × Clear all
NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Completed
145 enrolled 47 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡